Although prostate-specific antigen (PSA) is the most widely used biomarker for early diagnosis and follow-up [3], its specificity for PCa is poor, leading to unnecessary biopsies, over-diagnosis, and over-treatment [4]. This evidence concerns the gene KLK3 and posterior cortical atrophy.